Alexandra Leary, MD, PhD, discusses PFS and safety data from the phase 2 TEDOVA trial of Tedopi plus pembrolizumab in platinum-sensitive ovarian cancer.
Alexandra Leary, MD, PhD
Advertisement
Articles by Alexandra Leary, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
Phase 3 eVOLVE-Lung02 Trial of First-Line Volrustomig Is Discontinued in First-Line Metastatic NSCLC
4
Five Under 5: Top Oncology Videos for the Week of 8/9
5